| 查看: 2673 | 回复: 4 | |||
[交流]
投稿International Journal of Cancer被拒了，老板要我argue，大家看看可能吗？ 已有3人参与
|
|
文章被拒了，但是看了下评论，老板要我argue，大家说我是按照意见修改了再argue还是先argue要求修改，再补数据，argue希望大吗？ 以下是审稿意见： 05-Mar-2014 Re: IJC-14-0243 Dear XXX: Thank you for submitting your manuscript XXX to the International Journal of Cancer. Our reviewing process has now been completed, and your paper has been reviewed by three outside referees and studied by the Editors. After careful consideration, we regret to say that we find your manuscript unsuited for publication in the IJC. Our decision is based on the lower priority of the work in light of current competition for publication and our stringent criteria. You can view the reviewer comments below. We do hope that you find the reviews helpful and remain sorry that our answer cannot be a positive one. Thank you for your interest in IJC. We hope that this decision will not dissuade you from submitting your work again in the future. Yours sincerely, Prof. Peter Lichter Editor-in-Chief International Journal of Cancer Reviewer: 1 Comments to Author The manuscript by XXX shows that XXXXX（我的文章内容概括）and therefore we see significant bystander effect. The data are robust and clear. Major criticisms: In my opinion, this study lacks novelty,given that a recently published paper by the same group addressed similar questions except liposomes part. （但是我两篇文章看下创新点完全不一样啊，这篇是上篇的深入化，效果加强了，而且研究了机制,完全不一样啊，之前是一个载体靶向现在是双靶向啊）。 Reviewer: 2 Comments to Author The manuscript entitled XXX demonstrates XXX（我的文章内容)。 The authors showed XXX（文章的创新点和结论，第二个评委都看懂这篇的创新意义了）。 Although there are a few points that need to be clarified, the manuscript is well written: 1. Page 5, line 31:XXX（说我一个概念不够全）. Please consider adding the following citation to the text (one example of many): XXX(需要添加的文献）。 2. Page 5, line 41: XXX （也是一个概念需要补充）. Relevant reference can be: XXX(需要添加的文献） 3. Page 7, line 51-57:XXX (我的一个结果）. Can the authors clarify the reason for not choosing the same administration route for XXX（一个需要解释为什么实验这么做的地方）? 4. Efficacy study: Did the authors perform an in vivo survival study XXX(要求补充一个体内实验） 5. Page 18, line 54: "XXX“（我的一个结论）. Please mention the reason for it: large-sized particles. （就是文字改动下） 6. Did the authors perform long-term storage stability analysis for the liposomal formulation （就是补充一个稳定性实验，其实做了只是没放上去，不成问题）? Reviewer: 3 Comments to Author The authors looked at the therapeutic efficacy of XXXX（文章内容）. The study demonstrates significant XXX (实验结果）, and showed potential for safe and efficient gene therapy （创新点和临床应用）. Following concerns need to be addressed: 1. Figure 2D versus 2E: The authors used XXX （让我补充一个对毒性数据的解释说明） 2. Figure 4E: The high apoptosis with XXX （我的药物） would be better reflected by quantitative data. Please provide the comparative data with ratio of apoptotic cells in a given region with each formulation. 3. Figure 4F: The goal of XXX （我的研究目的）. The integrity of the normal lung tissue would be best understood if a histologic score with each formulation is provided. 4. Many errors occur throughout the manuscript which need revision. （看来意思是需要语言上的改进，还是有语法错误） Thanks. [ 发自手机版 http://muchong.com/3g ] [ Last edited by titankop on 2014-3-7 at 14:56 ] |
回复此楼» 猜你喜欢
材料专硕283求调剂
已经有7人回复
-
一志愿北京2，材料与化工308求调剂
已经有4人回复
-
求调剂
已经有5人回复
-
一志愿9材料学硕297已过六级求调剂推荐
已经有8人回复
-
278求调剂
已经有9人回复
-
285求调剂
已经有5人回复
-
一志愿武理材料工程302调剂环化或化工
已经有20人回复
-
348求调剂
已经有3人回复
-
本科211 分数293请求调剂
已经有3人回复
-
一志愿南农090401，268，求调剂
已经有4人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- JAS投稿被拒，还有机会Argue么？
已经有10人回复
- British Journal of Cancer投稿
已经有9人回复
- 情人节被《分析化学》拒稿了，伤心ing。argue有用吗？
已经有12人回复
- JACS被拒稿，大家看看argue有戏么
已经有30人回复
- 稿件被拒，想和编辑argue 具体怎么写，有没有模板？
已经有4人回复
- 悲催被拒，但不能接受被拒理由，可能跟editor argue？
已经有14人回复
- 文章被拒，想argue，该怎么说
已经有13人回复
kingki
至尊木虫 (知名作家)
- 应助: 465 (硕士)
- 金币: 23654.3
- 散金: 6301
- 红花: 18
- 帖子: 7935
- 在线: 601.3小时
- 虫号: 514983
- 注册: 2008-02-29
- 性别: GG
- 专业: 电化学
2楼2014-03-07 14:40:59
3楼2014-03-07 14:42:51
4楼2018-03-20 15:47:24
国际科学编辑 
铁杆木虫 (知名作家)
- 应助: 1532 (讲师)
- 金币: 3627.6
- 散金: 615
- 红花: 275
- 沙发: 3
- 帖子: 7972
- 在线: 146.9小时
- 虫号: 4407167
- 注册: 2016-02-16
- 性别: GG
- 专业: 病原微生物变异与耐药
5楼2018-03-21 10:21:15
